Division of Radiation Oncology, Shizuoka Cancer Center, Sunto, Shizuoka, Japan.
Int J Clin Oncol. 2009 Dec;14(6):507-12. doi: 10.1007/s10147-009-0907-2. Epub 2009 Dec 5.
The purpose of this study was to retrospectively compare the survival and toxicities associated with chemoradiotherapy using full-dose and weekly regimens in patients with stage III non-small cell lung cancer.
Consecutive patients who received concurrent chemoradiotherapy between October 2002 and June 2006 at our institution were enrolled. The prescribed dose for thoracic radiotherapy was 60 Gy in 30 fractions for all the patients.
Fifty-nine patients were enrolled; 36% of the patients were treated with full-dose regimens and 64% with weekly regimens. The patient characteristics were similar in the two groups. In both univariate and multivariate analyses, treatment with weekly regimens was associated with a better overall survival than that with full-dose regimens (2-year survival rates: 75% for weekly regimens vs 41% for full-dose regimens). The toxicities and compliance in the two groups were comparable.
Weekly regimens exhibited more favorable overall survival as compared to full-dose regimens in this retrospective study. Confirmation of the results by a randomized phase III trial is warranted.
本研究旨在回顾性比较全剂量和每周方案在 III 期非小细胞肺癌患者中的生存和毒性。
本研究纳入了 2002 年 10 月至 2006 年 6 月期间在我院接受同期放化疗的连续患者。所有患者的胸放疗规定剂量为 60Gy，共 30 个分次。
共纳入 59 例患者；全剂量组占 36%，每周剂量组占 64%。两组患者的特征相似。单因素和多因素分析均显示，每周方案治疗的总生存率优于全剂量方案（2 年生存率：每周方案为 75%，全剂量方案为 41%）。两组的毒性和依从性相当。
在这项回顾性研究中，与全剂量方案相比，每周方案显示出更有利的总生存。需要通过随机 III 期试验来证实这些结果。
